QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Qiagen (QGEN) Tops Q1 EPS by 3c, Revenues Beat; Reaffirms FY21 EPS Outlook
May 3, 2021 4:26 PM EDTQiagen (NYSE: QGEN) reported Q1 EPS of $0.66, $0.03 better than the analyst estimate of $0.63. Revenue for the quarter came in at $567.2 million versus the consensus estimate of $557.5 million.
Q1 2021 net sales rise 52% (48% CER) to $567.2 million, exceeds outlook for at least 45% CER growth; adj. EPS up 94% to $0.66 ($0.65 CER), exceeds outlook for ~$0.60-0.62 CER16% CER growth to $364 million from non-COVID product groups, represent 64% of total sales, while COVID-19 product group sales rise 186% CER to $203 millionQ1 2021 operating cash flow rises over 700% to $128.6 million, free... More